FDA Adverse Event Malfunction Summary report: N

COBAS INTEGRA CALCIUM

MDR report key: 1930385 · Received December 16, 2010

Report

Report Number
1823260-2010-07504
Event Type
Malfunction
Date Received
December 16, 2010
Date of Event
October 18, 2010
Report Date
December 16, 2010
Manufacturer
ROCHE DIAGNOSTICS
Product Code
CIC
PMA / PMN Number
K963292
Removal / Correction Number
1823260-09/27/10-003-R
Product Problem
Yes
Report Source
Manufacturer report
Reporter Location
PR, US
Reporter Occupation
HEALTH PROFESSIONAL

Narratives

Description of Event or Problem · 1

THE USER RECEIVED ABNORMAL HIGH CALCIUM RESULTS FOR PATIENTS WITH NO HISTORY OF HYPERKALEMIA FROM THE INTEGRA 800 SERIAL NUMBER (B)(4). THE USER PROVIDED DATA FOR ONE PATIENT SAMPLE. ALL RESULTS ARE IN MG/DL. THE RESULTS FOR THE PATIENT SAMPLE WERE 8.32, 8.14 AND 7.69. AFTER CALIBRATION THE SAMPLE WAS REPEATED AND THE RESULT WAS 9.26. THE REPEAT TESTING WAS PERFORMED ON (B)(6) 2010. THE ERRONEOUS RESULTS WERE REPORTED OUTSIDE THE LABORATORY. NO ADVERSE EVENTS WERE ALLEGED REGARDING THE ISSUE. INTERNAL INVESTIGATIONS REVEALED THE PRESENCE OF PRECIPITATE IN REAGENT 2 (R2) OF THE CALCIUM REAGENT LOT. THE ROOT CAUSE FOR THE PRECIPITATION IS STILL UNDER INVESTIGATION. AN URGENT MEDICAL DEVICE REMOVAL NOTICE WAS MAILED (B)(6) 2010 TO ALL CUSTOMERS TO IMMEDIATELY DISCONTINUE USE OF THE CALCIUM REAGENT LOT. CALCIUM DEVIATIONS OF > 20% ABOVE AND BELOW THE REFERENCE RANGE ARE CONSIDERED CRITICAL. THESE DEVIATIONS COULD LEAD TO NON-DETECTION OF A PATHOLOGICAL STATUS OR MAY LEAD TO UNNECESSARY THERAPEUTIC CONSEQUENCES. THE ERRONEOUS BIAS CAUSED BY THIS ASSAY LOT MAY CAUSE PATIENT SAMPLES WITH CRITICALLY HIGH OR CRITICALLY LOW CALCIUM LEVELS TO HAVE RESULTS THAT APPEAR TO BE IN THE NORMAL RANGE. THESE PATIENTS MAY BE AT HIGH RISK FOR MISDIAGNOSIS OF PATHOLOGICAL CONDITIONS ASSOCIATED WITH ABNORMAL CALCIUM LEVELS. INACCURATELY HIGH CALCIUM VALUES MAY LEAD TO AN INCORRECT DIAGNOSIS DEPENDING ON THE BLOOD CALCIUM LEVEL. IN THE WORST CASE, THE WRONG THERAPY MAY BE INITIATED. SUSPECTED HYPERCALCEMIA WOULD MEAN CONFIRMING THE CALCIUM VALUE QUICKLY, AND TREATMENT WOULD OCCUR ACCORDING TO THE CLINICAL PICTURE. A PATIENT NORMALLY SHOWS OBVIOUS SYMPTOMS IF THE CALCIUM VALUE IS >12 MG/DL. IN THE CASE OF INACCURATELY LOW VALUES, THE CALCIUM VALUE MUST BE INTERPRETED TOGETHER WITH OTHER PARAMETERS (E.G., MAGNESIUM, PHOSPHATE, AND PTH). UNNECESSARY FURTHER EXAMINATION AND BLOOD COLLECTION MAY RESULT.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
1 COBAS INTEGRA CALCIUM CRESOLPHTHALEIN COMPLEXONE, CALCIUM CIC ROCHE DIAGNOSTICS NA 62601901

Patients

Seq Age Sex Outcome Treatment
1